IND submission is a major milestone in the life of your drug. We can provide all supporting analytical data to help ensure a smooth application process.
We have the expertise, flexibility, and resources to provide a full range of pharmaceutical API custom development services at every stage of the lifecycle.
We can provide lab-, kilo- and pilot-scale manufacturing for preclinical studies and all phases of clinical trials, supplying milligram to kilogram quantities.
Cambrex brings more than 40 years of generic API manufacturing experience to its pharmaceutical partners. From our sites in Italy, Sweden, and the USA, we are a leading global supplier of generic APIs.
Drug substance tech transfer sounds so simple on the surface, but it’s a complex activity carrying a number of technical, regulatory, and quality risks.
At Snapdragon Chemistry, now part of Cambrex, our chemists specialize in creating custom solutions and technologies to take on your toughest process development and production challenges. This includes expertise in designing and building reactors that enable seamless technology transfer as a process scales up for commercial manufacturing.
At Cambrex, we provide a range of technologies equipped to solve your API manufacturing challenges, and we are flexible enough to handle the most complex molecules.
You can rely on our extensive portfolio of analytical development solutions and testing services to rapidly advance your molecule for the greatest chance of success.
We’re solid state chemistry experts who can deliver timely, phase-appropriate solutions to optimize the physical stability of your API, develop a more bioavailable formulation or overcome other challenges.
Cambrex’s experienced analysts are well-equipped to ensure microbial testing is of the highest quality for our customers and delivered with a quick and reliable turnaround.
Cambrex and Q1 Scientific’s stability storage and sample management capabilities provide a variety of pharmaceutical storage conditions, with walk-in and reach-in chambers that meet all ICH Q1A requirements.
Cambrex offers extensive development services tailored to meet your drug product needs in early development. From pre-formulation to Phase II, we ensure your products are developed with speed, flexibility, and quality in mind.
Whether you need rapid development, flexible manufacturing solutions, or high-quality production, Cambrex is your trusted partner for advancing your drug product from concept to the clinic.
Cambrex is here to support you in early-phase development. Our development experts apply their ingenuity and skill to address your unique challenges.
Our teams of creative problem-solvers work closely with you to accelerate drug development timelines, optimize processes, and meet regulatory requirements.
We understand that the commercial phase of drug development can be challenging, especially when it comes to manufacturing at scale and meeting changing market demands.
Cambrex is a leading global supplier of more than 70 generic APIs, as well as intermediates and derivatives.
09.26.2024
This collaboration will integrate Atinary’s AI-driven and automated process optimization technology with Snapdragon’s state-of-the-art laboratories and process development capabilities to tackle complex challenges in drug development.
Lausanne, Switzerland — September 26, 2024 — Atinary Technologies, whose leading no-code AI platform, SDLabs™, and Self-Driving Labs™ technology are transforming research and development (R&D) of new molecules and chemicals, is thrilled to announce a strategic collaboration with Snapdragon Chemistry, a Cambrex company. Snapdragon is a recognized leader in API process development, with specialization in continuous flow process development, lab automation and complex synthetic APIs.
Through this collaboration, Snapdragon integrated its proprietary LabOS™ software platform with Atinary’s SDLabs™ platform to build a fully-automated and AI-driven, medium-throughput Solid-Phase Oligonucleotide Synthesizer (SPOS) for the purpose of autonomous multi-objective process optimizations. By using Atinary’s AI platform, Snapdragon’s process optimization campaign has demonstrated significant improvements across the tested applications, with up to an 18% increase in product yield and a 22% reduction in cost compared to processes previously optimized by an experienced scientist.
“Atinary is committed to accelerating innovation and delivering cutting-edge solutions to our customers,” said Dr. Hermann Tribukait, Co-Founder and CEO of Atinary Technologies. “Our work with Snapdragon showcases the power of our AI and data-driven process to solve complex chemistry and molecular discovery challenges in the pharmaceutical and biotech industry, orders of magnitude faster than traditional methods.”
Snapdragon’s state-of-the-art laboratories and process development capabilities, along with their ability to design and build self-contained reactors, will be instrumental in this collaboration.
“We are excited about the opportunity to expand Snapdragon’s technological capability by integrating Atinary’s AI technology in our process R&D activities”, said Dr. Eric Fang, General Manager of Snapdragon Chemistry. “We believe that our combined expertise and shared vision for accelerated innovation will lead to significant advancements and added value for our customers, streamlining and expediting drug development pipelines and R&D portfolios.”
About Atinary Technologies Atinary accelerates optimization and discovery of breakthrough molecules and materials for our clients in pharma, biotech, consumer packaged goods, chemicals, energy, and climate tech. The sweet spot applications of our no-code AI platform and self-driving labs technology are in formulation, catalysis, and synthesis. Atinary’s vision is to transform R&D for the good of society. We aspire to accelerate the transition to a healthier and sustainable future by developing AI solutions that revolutionize science and R&D. For more information visit us at https://atinary.com/ and on Linkedin Atinary Technologies.
About Snapdragon Chemistry Snapdragon Chemistry, a Cambrex company, specializes in active pharmaceutical ingredient (API) batch and continuous flow process development, utilizing state-of-the-art automation technology and proprietary equipment to solve complex process and analytical development challenges. With R&D and manufacturing headquartered in Waltham, Massachusetts, Snapdragon’s 70+ employees come with strong ties to the local scientific community, including more than 30 PhD scientists on staff.
About Cambrex Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical and IND enabling services.
With over 40 years of experience and a team of 2,000 experts servicing global clients from North America and Europe, Cambrex offers a range of specialized drug substance technologies and capabilities, including continuous flow, controlled substances, solid-state science, material characterization, and highly potent APIs.